Buzzy Plus EMLA Cream for Vascular Access in Children

NCT ID: NCT04695054

Last Updated: 2024-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

94 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Venepuncture and peripheral intravenous cannulation are commonly performed in children and may cause substantial pain and distress. The aim of this study is to evaluate the efficacy of the combination of EMLA cream and Buzzy device in pain and distress relief during venipuncture or peripheral vascular access in hospitalized children.

The study is an open randomized controlled study. Eligible children will be randomized to receive the application of EMLA cream 60 minutes before the needle procedure or the application of EMLA 60 minutes before the procedure and the use of Buzzy device during procedure.

The primary study outcome will be the mean distress score experienced by children at the moment of the procedure, evaluated with the CEMS scale. Secondary outcomes will be the mean distress score recorded by operators; the self-reported mean pain score; the mean pain score reported by parents and operators.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Access

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Buzzy and EMLA Cream

In the experimental group children will receive the application of EMLA cream 60 minutes before the needle procedure and the use of Buzzy device during the procedure.

Group Type EXPERIMENTAL

Buzzy device plus EMLA cream

Intervention Type DEVICE

EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure

EMLA Cream

In the control group children will receive the application of EMLA cream 60 minutes before the needle procedure

Group Type ACTIVE_COMPARATOR

Only EMLA cream

Intervention Type DRUG

EMLA cream will be applied 60 minutes before the needle procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buzzy device plus EMLA cream

EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure

Intervention Type DEVICE

Only EMLA cream

EMLA cream will be applied 60 minutes before the needle procedure

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children between 4 and 12yrs of age needing venipuncture or peripheral vascular access
* children who have applied EMLA cream at least 60 minutes before the procedure

Exclusion Criteria

* children with cognitive impairment
* children with skin lesion that does not allow the application of Buzzy device
* children diseases that cause hypersensibility to cold (i.e. Raynaud syndrome, sickle cell disease)
* children who have taken any analgesics in the 8 hours before enrollment
Minimum Eligible Age

4 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS Burlo Garofolo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tamara Strajn, Nurse

Role: PRINCIPAL_INVESTIGATOR

Institute for Maternal and Child Health IRCCS Burlo Garofolo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS materno infantile Burlo Garofolo

Trieste, TS, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC 12/2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Buzzy® Application in Pain
NCT04990648 COMPLETED NA